Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer
Actuate Therapeutics, Inc.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Voss Capital Travis Cocke | 1,300,000 | $7,956,000 | +46% | 0.38% |
| 2. | Prosight Capital Lawrence Hawkins | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.00 | 71,428 | $499,996.00 | 196,428 | 2025-06-27 | Filing | |
| $7.00 | 71,428 | $499,996.00 | 196,428 | 2025-06-27 | Filing | |
| $7.00 | 71,428 | $499,996.00 | 196,428 | 2025-06-27 | Filing | |
| $8.00 | 125,000 | $1,000,000.00 | 125,000 | 2024-08-14 | Filing | |
| $8.00 | 375,000 | $3,000,000.00 | 1,259,427 | 2024-08-14 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.80 | 280,000 | $1,624,000.00 | 904,795 | 2026-01-05 | Filing | |
| $8.00 | 2,324 | $18,592.00 | 131,248 | 2024-08-14 | Filing | |
| $8.00 | 17,361 | $138,888.00 | 980,433 | 2024-08-14 | Filing | |
| $8.00 | 5,314 | $42,512.00 | 300,143 | 2024-08-14 | Filing | |
| $8.00 | 2,324 | $18,592.00 | 131,248 | 2024-08-14 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 400,529 | $1,097,449 | 0% | |
| 2. | 62,592 | $171,502 | 0% | |
| 3. | 55,536 | $152,169 | 0% | |
| 4. | 36,398 | $99,731 | 0% | |
| 5. | 31,396 | $86,025 | 0% |